Evolutionary Scale

Meta AI spin-out behind ESM3 — the protein language model that "simulated 500M years of evolution" — whose team joined Biohub (Chan Zuckerberg Initiative) in November 2025.

1. Core Product / Service

Evolutionary Scale built ESM3, a multimodal generative protein model that reasons jointly over sequence, structure, and function, trained on billions of proteins (a 98B-parameter frontier variant plus smaller open releases) [1]. Its signature demonstration: generating esmGFP, a novel fluorescent protein at ~58% sequence identity to known GFPs — characterized as computationally simulating ~500M years of evolution [1]. Smaller variants (1.4B, 7B) were released open-weights for non-commercial research, with commercial access licensed to pharma via NVIDIA's BioNeMo [1].

Architecturally, ESM3 is a protein-specialized model, not a general LLM — earlier research stressed it carries no language-pretraining signal and instead represents sequence/structure, distinct from general-purpose models [local].

2. Target Users & Pain Points

• Pharma / biotech licensing commercial access for protein engineering and drug-discovery tasks.
• Academic researchers using the open non-commercial weights.

Pain solved: protein design traditionally requires costly directed evolution or screening; ESM3 generates function-conditioned sequences directly, collapsing search space.

3. Competitive Landscape

4. Unique Observations

• The "Meta spinoff" arc: the team left Meta after the company dissolved its AI-protein group during the 2023 efficiency cuts, raised a record seed, shipped ESM3, then on 2025-11-06 its team joined Biohub (the entity formed from CZI and CZ Biohub) in an undisclosed-terms transaction — officially described as the team "joining", not an acquisition [3] — a full cycle from big-tech research → venture startup → philanthropic research institute [1].
• General-LLM vs specialized-model debate: ESM3 is the clearest counterexample to the "just post-train a general LLM on protein data" thesis — earlier research found general LLMs (GPT-4o ~0.6, DeepSeek-R1 ~0.57 BERTScore) lag far behind protein-specialized models on protein tasks, with ESM3 as the canonical specialized model [local].
• Status change matters for the sector: its move into Biohub — effectively ending the independent commercial route — is the first exit of a pure-model protein company that did not commercialize on its own, and removes one of the few independent, well-capitalized protein-model companies from the commercial field, reinforcing the trend toward consolidation and big-tech/philanthropic capture.

5. Financials / Funding

• Seed: $142M (announced June 2024; led by Nat Friedman, Daniel Gross, Lux Capital; strategic from Amazon + NVIDIA NVentures) [1].
• Later rounds — unverified: a $540M Series A (July 2025; ~$682M total, ~$3.3B valuation) appears only in a single aggregator profile [2] and could not be confirmed in primary sources; the only confirmed financing is the $142M seed [3].
• Exit: team joined Biohub (CZI) on 2025-11-06; terms undisclosed. Co-founder Alex Rives became Biohub head of science [3]. A ~50-person team size is reported by the aggregator only [2].

6. People & Relationships

• Co-founders: Alex Rives (CEO), Tom Sercu, Salvatore "Sal" Candido (CTO) — ex-Meta AI/FAIR ESM team.
• Investors: Lux Capital, Nat Friedman, Daniel Gross, Amazon, NVIDIA (NVentures), Khosla Ventures.
• Destination: Biohub / Chan Zuckerberg Initiative (team joined, Nov 2025).
• Peers: alphafold3, chai-discovery, isomorphic-labs.

Sources

• [1] EvolutionaryScale $142M launch coverage (2026-08-24)
• [2] AI Wiki — EvolutionaryScale profile (2026-08-24) — single aggregator source; funding figures beyond the seed are unverified
• [3] Research note: AI-bio wet-lab and business-model verification, Oct 2026 (compiles Biohub's announcement, Gunderson client note "EvolutionaryScale team joins Biohub", TechCrunch $142M coverage)